Product Royalties. Running Royalties in an amount equal to [***] of annual Net Sales of Type 1 Products.
Product Royalties. 6. The parties acknowledge that the Deep TMS system for treatment of depression, currently undergoing clinical trials, as more particularly described in clause 6.6 of the Company’s prospectus dated 26 February 2009 and in section 1 of the table in clause 6.13.4.1 therein (a copy of the relevant sections of the prospectus being attached herein as Appendix C) (“the Current Product”), falls within the scope of “Products”, as such term is defined in the R&L Agreement, and that the provisions of the R&L Agreement accordingly apply thereto. The provisions of clause 9.1.2 of the R&L Agreement notwithstanding, it is however agreed that the Company shall pay Yeda in respect of the Current Product as follows (and not, for the avoidance of doubt, as set forth in clause 9.1.2 of the R&L Agreement):
Product Royalties. (a) Green Cross shall pay to MacroGenics a royalty at the rate determined in accordance with the royalty chart included in Exhibit H attached hereto on Net Sales of Products for the Royalty Term.
Product Royalties. On a Product-by-Product basis, Novartis shall pay royalties on the Net Sales of each Product in the Territory, in all Indications in the Field, at the following rates, during the Royalty Term: Aggregate Net Sales of a Product in any Calendar Year during the Royalty TermRoyalty Rate Portion of Net Sales of such Product up to US$[*] [*]% Portion of Net Sales of such Product above US$[*] and up to and including US$[*] [*]% Portion of Net Sales of such Product above US$[*] and up to and including US$[*] [*]% Portion of Net Sales of such Product above US$[*] and up to and including US$[*] [*]% Portion of Net Sales of such Product above US$[*] [*]%
Product Royalties. Moderna shall pay Carisma royalties on Annual Net Sales, on a Product-by-Product basis, equal to the following portions of Annual Net Sales multiplied by the applicable royalty rate (each royalty rate, a “Royalty Rate”) for such portion during the applicable Royalty Term for each such Product in accordance with this Section 6.5 (the “Per Product Annual Net Sales”). For Per Product Annual Net Sales of Products, Moderna shall pay the applicable corresponding Royalty Rate set forth below: Per Product Annual Net Sales Royalty Rate Per Product Annual Net Sales above $[**], up to $[**] [**]% Per Product Annual Net Sales exceeding $[**] up to $[**] [**]% Per Product Annual Net Sales exceeding $[**] [**]% Each Royalty Rate set forth in the table above shall apply only to that portion of the Per Product Annual Net Sales of Products in the Territory during a Calendar Year that falls within the indicated range of Per Product Annual Net Sales (as represented in the left column in the table above).
Product Royalties. During the Product Royalty Term, following the First Commercial Sale of a Product, DS shall furnish to Zymeworks a written report for each Calendar Quarter showing the Net Sales by Product sold by DS and its Related Parties during the reporting Calendar Quarter and the Product Royalties payable under this Agreement in sufficient detail to allow Zymeworks to verify the amount of Product Royalties paid by DS with respect to such Calendar Quarter, including, on a country-by-country and Product-by-Product basis, the total gross amount invoiced for Product sold, the Net Sales of each Product, and the Product Royalties (in US dollars) payable and in total for all Products and the manner and basis for any currency conversion in accordance with Section 6.2. Reports shall be due no later than […***…]. Product Royalties shown to have accrued by each report provided under this Section 6.1.2 shall be due and payable on the date such report is due.
Product Royalties. OV shall pay Eisai royalties on Annual Net Sales equal to the following portions of Annual Net Sales multiplied by the applicable royalty rate for such portion during the applicable Royalty Term for each such Product in accordance with Section 7.2(f): Annual Net Sales Royalty Rate Annual Net Sales above $0, up to and including One Hundred Million U.S. Dollars ($100,000,000.00) [***] Annual Net Sales above One Hundred Million U.S. Dollars ($100,000,000.00), up to and including Two Hundred Fifty Million U.S. Dollars ($250,000,000.00) [***] Annual Net Sales above Two Hundred Fifty Million U.S. Dollars ($250,000,000.00), up to and including Five Hundred Million U.S. Dollars ($500,000,000.00) [***] Annual Net Sales above Five Hundred Million U.S. Dollars ($500,000,000.00) [***] Each Royalty Rate set forth in the table above will apply only to that portion of the Annual Net Sales of Product in the Territory during a given Calendar Year that falls within the indicated range. For example, if Annual Net Sales of Product in the Territory by OV, its Affiliates and sublicensees was Three Hundred and Fifty Million U.S. Dollars ($350,000,000), then the royalties payable with respect to such Annual Net Sales, subject to adjustment as set forth in this Section 7.2(a), would be: [***].
Product Royalties. A. Royalties. ********************************************************** ***************************************************************************** ***************. For each copy of the Products distributed by CA, CA shall pay Supplier a royalty equal to ******************************* by CA for the licensing of the Products by CA to Customers. For each copy of the Products licensed by Supplier, Supplier shall pay CA a marketing fee equal to ********************************* by Supplier for the licensing of the Products by Supplier to Customers. With respect to transactions denominated in currencies other than United States Dollars, the foreign currency amount will be converted into US Dollars in accordance with CA's generally accepted accounting principles before determining the resulting Net Revenues. If the Product is licensed or leased with other hardware or software products priced together or sold as a single unit or as a part of a combined lease or license of the Product with such other products (a "Bundled Product Sale"), then the Net Revenues arising from such Bundled Product Sales will be the pro-rata amount attributable to the Product, with such allocation being based on CA's and Supplier's standard list prices for all of the products included in the Bundled Product Sale in question.
Product Royalties. Subject to Section 6.7, during the Royalty Term, Lilly shall pay, or cause to be paid, to NextCure the following tiered royalties on Net Product Sales with respect to all Products Directed to a given Lilly Target in a Calendar Year: Portion of aggregate Net Product Sales for such Products in a Calendar Year Royalty rate applicable to such portion [***]
Product Royalties. For each calendar year during the term of this Agreement (beginning with 1995) CIGI shall pay to MBI a monthly royalty fee of one percent (1%) of Net Product Sales, payable as provided in Section 3.4. No royalty shall be paid on Net Product Sales which occur after expiration or termination of this Agreement.
